RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer

Gang Zhi Wang, Takuya Fukazawa, Toshio Nishikawa, Nobuyuki Watanabe, Kazufumi Sakurama, Takayuki Motoki, Shinji Hatakeyama, Osamu Omori, Toshiaki Ohara, Shunsuke Tanabe, Yasuhiro Fujiwara, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Yoshio Naomoto

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Esophageal cancer is one of the most frequently occurring cancers in the world. Targeting therapy strategy of cancer with specific inhibitors is developing and has showed promising antitumor efficacy. It is known that mTOR is an important controller of cell growth. RAD001 (everolimus) is a specific inhibitor of mTOR that can block the mTOR signaling pathway. The purposes of this study was to explore the inhibitory effects of RAD001 on mTOR signaling and the mechanism of cell growth suppression by RAD001. We examined both the expression of mTOR, p70S6K and S6 in SEG-1 esophageal cancer cells and KOB-13 normal esophageal epithelial cells and the efficacy of RAD001 against SEG-1 esophageal cancer cells. mTOR, p70S6K and S6 were overexpressed in SEG-1 esophageal cancer cells compared with KOB-13 normal esophageal epithelial cells. SEG-1 esophageal cancer cells were sensitive to RAD001. The survival rate of the cells treated with RAD001 over 0.33 μM was significantly different compared with that of control (P

Original languageEnglish
Pages (from-to)1167-1172
Number of pages6
JournalOncology Reports
Volume23
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Esophageal Neoplasms
70-kDa Ribosomal Protein S6 Kinases
S 6
Therapeutics
Epithelial Cells
Growth
Everolimus
Neoplasms

Keywords

  • Cell growth
  • Esophageal cancer cells
  • mTOR signaling
  • RAD001 (everolimus)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wang, G. Z., Fukazawa, T., Nishikawa, T., Watanabe, N., Sakurama, K., Motoki, T., ... Naomoto, Y. (2010). RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncology Reports, 23(4), 1167-1172. https://doi.org/10.3892/or-00000747

RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. / Wang, Gang Zhi; Fukazawa, Takuya; Nishikawa, Toshio; Watanabe, Nobuyuki; Sakurama, Kazufumi; Motoki, Takayuki; Hatakeyama, Shinji; Omori, Osamu; Ohara, Toshiaki; Tanabe, Shunsuke; Fujiwara, Yasuhiro; Takaoka, Munenori; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Tanaka, Noriaki; Naomoto, Yoshio.

In: Oncology Reports, Vol. 23, No. 4, 04.2010, p. 1167-1172.

Research output: Contribution to journalArticle

Wang, GZ, Fukazawa, T, Nishikawa, T, Watanabe, N, Sakurama, K, Motoki, T, Hatakeyama, S, Omori, O, Ohara, T, Tanabe, S, Fujiwara, Y, Takaoka, M, Shirakawa, Y, Yamatsuji, T, Tanaka, N & Naomoto, Y 2010, 'RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer', Oncology Reports, vol. 23, no. 4, pp. 1167-1172. https://doi.org/10.3892/or-00000747
Wang, Gang Zhi ; Fukazawa, Takuya ; Nishikawa, Toshio ; Watanabe, Nobuyuki ; Sakurama, Kazufumi ; Motoki, Takayuki ; Hatakeyama, Shinji ; Omori, Osamu ; Ohara, Toshiaki ; Tanabe, Shunsuke ; Fujiwara, Yasuhiro ; Takaoka, Munenori ; Shirakawa, Yasuhiro ; Yamatsuji, Tomoki ; Tanaka, Noriaki ; Naomoto, Yoshio. / RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. In: Oncology Reports. 2010 ; Vol. 23, No. 4. pp. 1167-1172.
@article{2fafedb940d849b1a79899533e03e841,
title = "RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer",
abstract = "Esophageal cancer is one of the most frequently occurring cancers in the world. Targeting therapy strategy of cancer with specific inhibitors is developing and has showed promising antitumor efficacy. It is known that mTOR is an important controller of cell growth. RAD001 (everolimus) is a specific inhibitor of mTOR that can block the mTOR signaling pathway. The purposes of this study was to explore the inhibitory effects of RAD001 on mTOR signaling and the mechanism of cell growth suppression by RAD001. We examined both the expression of mTOR, p70S6K and S6 in SEG-1 esophageal cancer cells and KOB-13 normal esophageal epithelial cells and the efficacy of RAD001 against SEG-1 esophageal cancer cells. mTOR, p70S6K and S6 were overexpressed in SEG-1 esophageal cancer cells compared with KOB-13 normal esophageal epithelial cells. SEG-1 esophageal cancer cells were sensitive to RAD001. The survival rate of the cells treated with RAD001 over 0.33 μM was significantly different compared with that of control (P",
keywords = "Cell growth, Esophageal cancer cells, mTOR signaling, RAD001 (everolimus)",
author = "Wang, {Gang Zhi} and Takuya Fukazawa and Toshio Nishikawa and Nobuyuki Watanabe and Kazufumi Sakurama and Takayuki Motoki and Shinji Hatakeyama and Osamu Omori and Toshiaki Ohara and Shunsuke Tanabe and Yasuhiro Fujiwara and Munenori Takaoka and Yasuhiro Shirakawa and Tomoki Yamatsuji and Noriaki Tanaka and Yoshio Naomoto",
year = "2010",
month = "4",
doi = "10.3892/or-00000747",
language = "English",
volume = "23",
pages = "1167--1172",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer

AU - Wang, Gang Zhi

AU - Fukazawa, Takuya

AU - Nishikawa, Toshio

AU - Watanabe, Nobuyuki

AU - Sakurama, Kazufumi

AU - Motoki, Takayuki

AU - Hatakeyama, Shinji

AU - Omori, Osamu

AU - Ohara, Toshiaki

AU - Tanabe, Shunsuke

AU - Fujiwara, Yasuhiro

AU - Takaoka, Munenori

AU - Shirakawa, Yasuhiro

AU - Yamatsuji, Tomoki

AU - Tanaka, Noriaki

AU - Naomoto, Yoshio

PY - 2010/4

Y1 - 2010/4

N2 - Esophageal cancer is one of the most frequently occurring cancers in the world. Targeting therapy strategy of cancer with specific inhibitors is developing and has showed promising antitumor efficacy. It is known that mTOR is an important controller of cell growth. RAD001 (everolimus) is a specific inhibitor of mTOR that can block the mTOR signaling pathway. The purposes of this study was to explore the inhibitory effects of RAD001 on mTOR signaling and the mechanism of cell growth suppression by RAD001. We examined both the expression of mTOR, p70S6K and S6 in SEG-1 esophageal cancer cells and KOB-13 normal esophageal epithelial cells and the efficacy of RAD001 against SEG-1 esophageal cancer cells. mTOR, p70S6K and S6 were overexpressed in SEG-1 esophageal cancer cells compared with KOB-13 normal esophageal epithelial cells. SEG-1 esophageal cancer cells were sensitive to RAD001. The survival rate of the cells treated with RAD001 over 0.33 μM was significantly different compared with that of control (P

AB - Esophageal cancer is one of the most frequently occurring cancers in the world. Targeting therapy strategy of cancer with specific inhibitors is developing and has showed promising antitumor efficacy. It is known that mTOR is an important controller of cell growth. RAD001 (everolimus) is a specific inhibitor of mTOR that can block the mTOR signaling pathway. The purposes of this study was to explore the inhibitory effects of RAD001 on mTOR signaling and the mechanism of cell growth suppression by RAD001. We examined both the expression of mTOR, p70S6K and S6 in SEG-1 esophageal cancer cells and KOB-13 normal esophageal epithelial cells and the efficacy of RAD001 against SEG-1 esophageal cancer cells. mTOR, p70S6K and S6 were overexpressed in SEG-1 esophageal cancer cells compared with KOB-13 normal esophageal epithelial cells. SEG-1 esophageal cancer cells were sensitive to RAD001. The survival rate of the cells treated with RAD001 over 0.33 μM was significantly different compared with that of control (P

KW - Cell growth

KW - Esophageal cancer cells

KW - mTOR signaling

KW - RAD001 (everolimus)

UR - http://www.scopus.com/inward/record.url?scp=77949435090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949435090&partnerID=8YFLogxK

U2 - 10.3892/or-00000747

DO - 10.3892/or-00000747

M3 - Article

VL - 23

SP - 1167

EP - 1172

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -